Developing both prophylactic 
and therapeutic effective 
countermeasures

Crimean Congo Haemorrhagic Fever 
Vaccine & Immunotherapy

The CCHFVACIM project aims to address the serious public health threat posed by Crimean Congo Haemorrhagic Fever Virus (CCHFV), a tick-borne zoonotic virus that causes fatal epidemics in humans. This is one of the most threatening vector-borne pathogens, widely distributed, including on the European continent. Currently, there are no preventive or effective therapeutic measures available against CCHFV, which is listed as a key priority in the WHO’s R&D Blueprint list of infectious agents with epidemic or pandemic potential.

Deep structural biology studies on viral glycoproteins and investigation of the immunogenicity of the viral antigens will be combined with optimisation of a mRNA vaccine candidate against the virus and characterisation of the resulting protective immunity, as well as with the development of immuno-therapeutic monoclonal antibodies (mAbs) based on CCHFV’s antigenic targets.


Numbers

0

partners

0

countries

0

years EU-funded

project

0M

€

News

  • CCHFVACIM Kick-Off Meeting on March 19-20, 2024 in Paris

    The CCHFVACIM Kick-Off Meeting aimed to establish the project’s foundational framework, ensuring effective collaboration among consortium members to advance research and innovation in combating Crimean-Congo hemorrhagic fever. The CCHFVACIM project will employ deep structural biology studies on viral glycoproteins, investigation of immunogenicity of viral antigens, and optimization of an mRNA vaccine candidate against CCHFV. Additionally,…